BOSTON, Massachusetts, and Seoul, South Korea — August 18, 2026
Ingenia Therapeutics announced that its shares have begun trading on the KOSDAQ market, marking a major corporate milestone for the clinical-stage biotechnology company as it moves to accelerate development of its next-generation vascular antibody therapeutics. The public listing is expected to support Ingenia’s efforts to advance its proprietary vascular stabilization pipeline and expand its global commercialization strategy. Founded in Boston in 2018, the company is developing antibody-based medicines designed to address diseases associated with vascular instability and dysfunction. Ingenia’s technology platform originated from research conducted at KAIST and the Institute for Basic Science (IBS) and is built around two core approaches, TIE-body and LCIDEC. Through these technologies, the company aims to directly activate the TIE2 vascular stabilization pathway and selectively target disease-associated proteins within endothelial cells. The KOSDAQ debut therefore represents more than a financing milestone for Ingenia, providing a platform to support the company’s broader clinical pipeline expansion, technology development and international growth strategy.
Late-Stage Retina Program Remains a Key Pipeline Driver
A major focus of Ingenia’s pipeline is IGT-427 (MK-8748), an investigational bispecific antibody designed to combine TIE2 agonism and VEGF inhibition for vascular diseases of the retina. The candidate is being evaluated in late-stage clinical development for patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Ingenia’s approach is designed to address retinal vascular instability by activating TIE2 while simultaneously inhibiting VEGF signaling. The program also reflects the company’s strategy of developing therapies that target the underlying vascular biology of disease rather than relying solely on conventional pathway inhibition. Ingenia entered into a research collaboration and licensing agreement with EyeBio in 2022, and EyeBio was subsequently acquired by Merck, becoming a wholly owned subsidiary. The continued development of IGT-427 provides Ingenia with an important late-stage asset and demonstrates the potential commercial relevance of its vascular-targeting technology platform.
IPO Supports Expansion of Mid-Stage Clinical Pipeline
Beyond IGT-427, Ingenia plans to use the momentum from its KOSDAQ listing to accelerate several additional clinical and preclinical programs. IGT-303 is currently being evaluated in a Phase 2a clinical trial across Australia, New Zealand and South Korea for chronic kidney disease, with the company targeting potential global out-licensing in 2027. The company is also advancing IGT-532, an investigational solid-tumor program designed around its vascular-targeting technology and intended to provide a differentiated approach compared with conventional VEGF/PD-1 bispecific antibodies. Additional pipeline programs include IGT-302 for glaucoma and IGT-627 for pulmonary arterial hypertension. Ingenia said these programs are being supported by research collaborations with institutions including Harvard Medical School and Emory University School of Medicine, reflecting its broader strategy of combining proprietary platforms with external scientific expertise.
Advertisement
Vascular Technology Platform Expands Development Opportunities
Ingenia’s broader development strategy is centered on addressing vascular dysfunction across multiple therapeutic areas through its proprietary TIE-body and LCIDEC platforms. TIE-body is designed to directly activate TIE2, a receptor involved in maintaining vascular stability, while LCIDEC is intended to enable ligand capture and internalization into endothelial cells, providing a mechanism for selectively targeting disease-associated proteins. The company believes these technologies could create opportunities across ophthalmology, oncology, kidney disease and cardiovascular-related conditions. With the KOSDAQ listing now providing a new corporate platform, Ingenia is positioned to increase investment in clinical development, advance its diversified pipeline and pursue additional global partnerships. Chief Executive Officer Sangyeul Han, PhD, described the public-market debut as a transformative milestone and emphasized the company’s objective of achieving key clinical milestones while building long-term value around its vascular therapeutic technologies.
Source: Ingenia Therapeuticspress relese
